The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 13, 2023

Filed:

Aug. 03, 2018
Applicants:

The Johns Hopkins University, Baltimore, MD (US);

Asclepix Therapeutics, Inc., Baltimore, MD (US);

Inventors:

Niranjan Pandey, Baltimore, MD (US);

Aleksander S. Popel, Baltimore, MD (US);

Jordan J. Green, Baltimore, MD (US);

Adam Mirando, Baltimore, MD (US);

Assignees:

The Johns Hopkins University, Baltimore, MD (US);

AsclepiX Therapeutics, Inc., Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/566 (2006.01); A61P 27/02 (2006.01); A61P 9/00 (2006.01); A61K 38/17 (2006.01); G01N 33/50 (2006.01); A61K 38/39 (2006.01);
U.S. Cl.
CPC ...
G01N 33/566 (2013.01); A61K 38/1777 (2013.01); A61K 38/39 (2013.01); A61P 9/00 (2018.01); A61P 27/02 (2018.01); G01N 33/5008 (2013.01); G01N 2333/70546 (2013.01); G01N 2500/02 (2013.01);
Abstract

The present invention in various aspects and embodiments involves pharmaceutical compositions prepared by contacting a candidate α- or β-integrin-binding molecule, or panel thereof, with an integrin heterodimer, and quantifying heterodimer disruption by the candidate molecule. An integrin-binding molecule, or derivative thereof, that disrupts the integrin heterodimer is selected and is formulated into a pharmaceutical composition for administration to a subject, e.g., who has a disease or disorder related to abnormal vascularization.


Find Patent Forward Citations

Loading…